Auto Amazon Links: No products found. Blocked by captcha.
A new daily pill has undergone trials that have shown it can assist patients in losing approximately 12% of their body weight over the course of 72 weeks. This pill, named orforglipron, is not yet licensed but the manufacturer, Eli Lilly, anticipates it could potentially be available as early as next year. The mechanism of action for orforglipron involves suppressing appetite and inducing a feeling of fullness in users.
According to preliminary results from a major trial, individuals on the highest dosage of orforglipron lost an average of 12 kilograms (equivalent to nearly two stone) over a span of 16 months. However, about 10% of participants ceased taking the pills due to side effects such as nausea and vomiting. In addition to weight loss, participants in the trial also experienced improvements in cholesterol levels, blood fats, and blood pressure.
Dr. Kenneth Custer from Eli Lilly stated that the company is aiming to submit the drug for licensing prior to the end of the year. They are also gearing up for a global launch in response to the pressing public health issue of obesity. How this new weight loss pill will compete in the market, which is currently dominated by injectable drugs like Mounjaro, Wegovy, and Ozempic, remains to be seen. Despite being less potent than injectables, there is expected to be a substantial demand for weight loss pills as a non-invasive strategy for combating obesity.
The oral pill developed by Eli Lilly, orforglipron, achieved a 12% weight loss in participants, whereas patients on Mounjaro, an injectable drug from the same company, experienced a 22% weight loss. The oral drug’s potential affordability compared to injectables may open up access to a larger number of patients seeking weight loss treatment. The full results from the trial of orforglipron will be divulged at the upcoming European Association for the Study of Diabetes annual meeting and subsequently published in a peer-reviewed journal.
Meanwhile, competitor Novo Nordisk has introduced an oral version of its injectable drug Wegovy, which has already been submitted for approval in the United States. Patients on the highest dose of Novo Nordisk’s daily pill reportedly lost around 15% of their body weight after 64 weeks, showcasing another potential player in the weight loss pharmaceutical market
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.